PT  - JOURNAL ARTICLE
AU  - Lye, Phetcharawan
AU  - Dunk, Caroline E.
AU  - Zhang, Jianhong
AU  - Wei, Yanxing
AU  - Nakpu, Jittanan
AU  - Hamada, Hirotaka
AU  - Imperio, Guinever E
AU  - Bloise, Enrrico
AU  - Matthews, Stephen G
AU  - Lye, Stephen J
TI  - SARS-CoV-2 cell entry gene ACE2 expression in immune cells that infiltrate the placenta in infection-associated preterm birth
AID  - 10.1101/2020.09.27.20201590
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.27.20201590
4099  - http://medrxiv.org/content/early/2020/09/29/2020.09.27.20201590.short
4100  - http://medrxiv.org/content/early/2020/09/29/2020.09.27.20201590.full
AB  - COVID-19 infection during pregnancy is associated with an increased incidence of preterm birth but neonatal infection is rare. We assessed pathways by which SARS-CoV-2 could access the placenta and contribute to fetal transmission. Placentas from pregnancies complicated with chorioamnionitis (ChA), exhibited increased expression of ACE2 mRNA. Treatment of 2nd trimester placental explants with LPS, induced an acute increase in cytokine expression followed by ACE2 mRNA. Placental ACE2 protein localized to syncytiotrophoblast, in fetal blood vessels and M1/M2 macrophage and neutrophils within the villous stroma. Increased numbers of M1 macrophage and neutrophils were present in the placenta of ChA pregnancies. Maternal peripheral immune cells (mainly granulocytes and monocytes) express the ACE2 mRNA and protein. These data suggest that in COVID19 positive pregnancies complicated by ChA, ACE2 positive immune cells have the potential to traffic SARS-CoV-2 virus to the placenta and increase the risk of vertical transmission to the placenta/fetus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementE.B. is supported by the Coordenacao de Aperfeicoamento Pessoal de Nivel Superior [CAPES]; finance code 001, CAPES-Print fellowship). S.J.L. is supported by a grant (FDN-143262) from the Canadian Institutes of Health Research (CIHR). S.G.M. is supported by a grant (FDN-148368) from the CIHR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval of this study was obtained from the Mount Sinai Hospital Research Ethics BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe submission contains no supplementary material